Tumor rejection antigen P1A (P1A) (P1A)

Tumor rejection antigen P1A (P1A) is a well-characterized cancer-testis antigen originally identified in the mouse P815 mastocytoma (Van den Eynde et al., 1991, Science). It is encoded by the Trap1 gene and is expressed exclusively in the testis and placenta among normal tissues, but is frequently upregulated in various malignant cell lines (Uyttenhove et al., 1997, Int J Cancer). As a tumor-associated antigen, P1A serves as a target for cytotoxic T lymphocytes (CTLs) when its immunodominant peptide, LPYLGWLVF, is presented by MHC class I molecules (Shrikant et al., 1999, J Exp Med). In the field of oncology, P1A is a critical model for studying T-cell activation, peripheral tolerance, and the efficacy of cancer vaccines (Rosato et al., 2001, Vaccine). While P1A itself is a murine antigen, it is functionally analogous to human cancer-germline antigens such as the MAGE family, making it a vital tool for preclinical immunotherapy research. Therapeutic interventions targeting P1A include peptide-based vaccines and TCR-engineered T cells designed to induce tumor-specific lysis. Challenges in targeting P1A include the potential for immune evasion through antigen loss and the need to overcome the immunosuppressive tumor microenvironment.

Other names

Trap1 (murine)P815 tumor antigenTumor-rejection antigen P1A

Stimulation of antigen-specific CD8+ cytotoxic T lymphocytes (CTLs) through MHC class I peptide presentation.